- Home
- APRE vs TLPH Comparison
APRE vs TLPH Comparison
Compare APRE & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- TLPH
- Stock Information
- Founded
- APRE 2006
- TLPH 2005
- Country
- APRE United States
- TLPH United States
- Employees
- APRE N/A
- TLPH N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- APRE Health Care
- TLPH Health Care
- Exchange
- APRE Nasdaq
- TLPH Nasdaq
- Market Cap
- APRE 15.8M
- TLPH 12.7M
- IPO Year
- APRE 2019
- TLPH 2011
- Fundamental
- Price
- APRE $4.08
- TLPH $0.69
- Analyst Decision
- APRE Strong Buy
- TLPH Strong Buy
- Analyst Count
- APRE 2
- TLPH 2
- Target Price
- APRE $15.50
- TLPH $4.50
- AVG Volume (30 Days)
- APRE 33.0K
- TLPH 112.7K
- Earning Date
- APRE 11-07-2024
- TLPH 03-05-2025
- Dividend Yield
- APRE N/A
- TLPH N/A
- EPS Growth
- APRE N/A
- TLPH N/A
- EPS
- APRE N/A
- TLPH N/A
- Revenue
- APRE $1,310,839.00
- TLPH $281,000.00
- Revenue This Year
- APRE $134.21
- TLPH N/A
- Revenue Next Year
- APRE N/A
- TLPH N/A
- P/E Ratio
- APRE N/A
- TLPH N/A
- Revenue Growth
- APRE 130.31
- TLPH N/A
- 52 Week Low
- APRE $2.15
- TLPH $0.50
- 52 Week High
- APRE $8.85
- TLPH $1.61
- Technical
- Relative Strength Index (RSI)
- APRE 62.50
- TLPH 50.24
- Support Level
- APRE $3.34
- TLPH $0.55
- Resistance Level
- APRE $4.41
- TLPH $0.69
- Average True Range (ATR)
- APRE 0.43
- TLPH 0.06
- MACD
- APRE 0.04
- TLPH 0.01
- Stochastic Oscillator
- APRE 54.19
- TLPH 67.28
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.